CHRNA7

Neuronal acetylcholine receptor subunit alpha-7 · P36544 · CHRNA7 on Sugi Atlas →

179,933 patent compounds predicted against CHRNA7, 97,643 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Stilonium (SCHEMBL26104)	1.00	19/20
Stilonium (SCHEMBL26105)	1.00	19/20
SCHEMBL80066	0.65	18/20
Bromide (SCHEMBL69311)	0.62	17/20
SCHEMBL80826	0.63	15/20
Alcuronium (SCHEMBL150079)	1.00	14/20
Alcuronium (SCHEMBL122972)	0.98	14/20
SCHEMBL80814	0.72	14/20
SCHEMBL81293	0.57	14/20
SCHEMBL81218	0.58	13/20
Bromide (SCHEMBL52420)	0.51	9/20
Bromide (SCHEMBL131195)	0.44	9/20
Dl-Anabasine (SCHEMBL117530)	1.00	8/20
Butyltriphenylphosphonium (SCHEMBL1063)	0.42	8/20
SCHEMBL112783	0.37	8/20
SCHEMBL34778	0.35	8/20
Nornicotine (SCHEMBL158145)	1.00	7/20
Nornicotine (SCHEMBL158146)	1.00	7/20
SCHEMBL89187	0.66	7/20
SCHEMBL137900	0.58	7/20

Clinical trials — most relevant to CHRNA7 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia	PHASE4	COMPLETED
Efficacy of the Use of Genetic Markers in the Choice of the Pharmacological Treatment of Smoking (GENTSMOKING)	PHASE4	COMPLETED
Galantamine for Cognition in People With Schizophrenia	PHASE4	COMPLETED
Postoperative Sugammadex After COVID-19	PHASE4	UNKNOWN
Transcranial Magnetic Stimulation in Patients with Dual Disorders	PHASE3	NOT_YET_RECRUITING
Varenicline (Chantix™) for the Treatment of Alcohol Dependence	PHASE2	COMPLETED
Safety and Efficacy of MEM 3454 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease	PHASE2	COMPLETED
Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease Experiments 1 & 2 - Proj #3	PHASE2	COMPLETED
A Phase II Trial of Varenicline for the Treatment of Cocaine Dependence	PHASE2	COMPLETED
Crossover Target Engagement Study of Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease (Project #3 - Experiment 3 [UdallP3E3])	PHASE2	COMPLETED
Nicotinic Receptors and Schizophrenia	PHASE1/PHASE2	WITHDRAWN
Varenicline for Methamphetamine Dependence	PHASE2	COMPLETED
Effect of Varenicline on Cognitive Function in Cigarette Smokers With Schizophrenia	PHASE2	COMPLETED
Safety Study of the Effect of Scelectium Tortuosum (as Zembrin®)in Aged Normals	PHASE1	COMPLETED
Nicotinic Receptor Genetic Variation and Alcohol Reward	PHASE1	RECRUITING
Brain Networks and Addiction Susceptibility	PHASE1	COMPLETED
Diclofenac Dose Response Study	PHASE1	RECRUITING
Brain Imaging in Tobacco Smokers During a Quit Attempt	PHASE1	COMPLETED
The Use of AVL-3288 to Potentiate the Attention-Enhancing Effects of Low-Dose Nicotine	PHASE1	WITHDRAWN
Investigation of the Drug Dimethoxbenzylidene Anabaseine in Treating Schizophrenia Patients	PHASE1	COMPLETED
Copy Number Variation in CHRNA7 Gene in Migraine and Gene Expression	nan	COMPLETED
A Study on Risk Mutations of Vulnerability Genes of Schizophrenia	nan	UNKNOWN
Neural Inhibition as a Mechanism of Nicotine Dependence Among Persons With Schizophrenia	nan	COMPLETED
Effects of Prazosin on the Attention-Enhancing Effects of Nicotine	nan	WITHDRAWN
Common Noradrenergic Mechanisms in Parkinson´s Disease and L-DOPA Induced Dyskinesia	nan	UNKNOWN
Genetic Research in Schizophrenia Using DNA Markers and Clinical Phenotypes	nan	COMPLETED
fMRI Study of Nicotinic Effect on Neurophysiology of Schizophrenia	nan	COMPLETED
Brain Imaging in Alzheimer's Disease	nan	COMPLETED
Reversal of Neuromuscular Blockade in Thoracic Surgical Patients	nan	COMPLETED
Influence of Ear Vagus Nerve Stimulator on Patients With IBS	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a CHRNA7 binder may also engage these)

Protein	Name	Similarity
P54131	—	1.000	P54131 →
Q05941	—	1.000	Q05941 →
Q866A2	—	1.000	Q866A2 →
P49582	—	1.000	P49582 →
P22770	—	0.996	P22770 →
Q494W8	—	0.993	Q494W8 →
P02717	—	0.985	P02717 →
Q68RJ7	—	0.982	Q68RJ7 →
P04758	—	0.981	P04758 →
P09484	—	0.981	P09484 →
P04759	—	0.980	P04759 →
P25109	—	0.979	P25109 →
P02716	—	0.978	P02716 →
P02713	—	0.976	P02713 →
P09690	—	0.976	P09690 →
P25110	—	0.976	P25110 →
Q9ERK7	—	0.975	Q9ERK7 →
CHRNB2	Neuronal acetylcholine receptor subunit beta-2	0.975	landscape →
CHRNA9	Neuronal acetylcholine receptor subunit alpha-9	0.974	landscape →
P43144	—	0.974	P43144 →
CHRND	Acetylcholine receptor subunit delta	0.973	landscape →
P49580	—	0.973	P49580 →
Q8JFN7	—	0.972	Q8JFN7 →
CHRNB1	Acetylcholine receptor subunit beta	0.972	landscape →
P12390	—	0.972	P12390 →
P05376	—	0.971	P05376 →
P26153	—	0.971	P26153 →
Q8SPU6	—	0.971	Q8SPU6 →
P19370	—	0.970	P19370 →
Q9PTS8	—	0.969	Q9PTS8 →